2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
- DOI
- 10.1136/ard-2022-223628
- Published
- 2023 Jun
- Container
- Annals of the rheumatic diseases
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/ard-2022-223628,
title = {2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.},
author = {Rodríguez-Carrio J and Burska A and Conaghan PG and Dik WA and Biesen R and Eloranta ML and Cavalli G and Visser M and Boumpas DT and Bertsias G and Wahren-Herlenius M and Rehwinkel J and Frémond ML and Crow MK and Rönnblom L and Versnel MA and Vital EM},
year = {2023},
journal = {Annals of the rheumatic diseases},
doi = {10.1136/ard-2022-223628},
url = {https://doi.org/10.1136/ard-2022-223628}
}RIS
TY - JOUR TI - 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. AU - Rodríguez-Carrio J AU - Burska A AU - Conaghan PG AU - Dik WA AU - Biesen R AU - Eloranta ML AU - Cavalli G AU - Visser M AU - Boumpas DT AU - Bertsias G AU - Wahren-Herlenius M AU - Rehwinkel J AU - Frémond ML AU - Crow MK AU - Rönnblom L AU - Versnel MA AU - Vital EM PY - 2023 JO - Annals of the rheumatic diseases DO - 10.1136/ard-2022-223628 UR - https://doi.org/10.1136/ard-2022-223628 ER -
APA
J, R., A, B., PG, C., WA, D., R, B., ML, E., G, C., M, V., DT, B., G, B., M, W., J, R., ML, F., MK, C., L, R., MA, V., & EM, V. (2023). 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.. Annals of the rheumatic diseases. https://doi.org/10.1136/ard-2022-223628
Source records
- pubmed · retrieved 2026-11-10T20:39:34.621Z